ChromoCure, Inc. Expands Capacity: Recent Mayo Clinic Findings Encourage Aneuploidy Research Worldwide
Published: Apr 13, 2010
RENO, NV--(Marketwire - April 13, 2010) -
MacReport Media Publishing
The Mayo Clinic findings that confirmed aneuploidy as a cause of cancer published in the December 2009 Cancer Cell journal have spurred research in an increasing number of respected research universities and institutions, all of which have published reports in 2010; including:
- Yunnan Normal University.
- University College London, Department of Pathology
- Hokkaido University
- Oslo University Hospital
- Universitat Autonoma de Barcelona
- Dartmouth University, Department of Biochemistry
- Tel Aviv University, Medical Department
- University of South Florida, H. Lee Moffitt Cancer Center University of Pune
- University of Texas, M. D. Anderson Cancer Center
The Company recently announced its Joint Venture and Technology Sharing Agreement with Genome Research Group. GRG's advanced Therapeutic Modeling Protocols, together with ChromoCure's landmark Chromosomal Scanning Technology, further strengthens the Company's leadership in Cancer Detection, Therapy and Cure, and puts new impetus to its groundbreaking Project Boveri: Finding the Cure.
The Company's proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently relied upon by pathologists, including genetic or protein biomarker detection.
ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.